To determine whether HSPD1 drives malignant phenotypes through glycolytic reprogramming, we treated HSPD1-overexpressing (OE-HSPD1) PCa cells with the glycolysis inhibitor 2-DG. The gene discussed is HSPD1; the disease is posterior cortical atrophy.